As of October 2025, there is still no cure for Alzheimer’s disease, a progressive neurodegenerative disorder that causes brain cell death and leads to worsening memory loss, cognitive decline, and daily functioning issues. Current treatments focus on managing symptoms or, in some cases, modestly slowing disease progression, but they do not halt or reverse the underlying damage.Current TreatmentsApproved medications primarily target brain chemicals to temporarily ease symptoms like memory problems and confusion:
- Cholinesterase inhibitors (e.g., donepezil, rivastigmine, galantamine): These boost levels of acetylcholine, a neurotransmitter involved in memory and learning.
- Memantine (Namenda): This regulates glutamate activity to protect brain cells from overexcitation. These drugs provide limited relief and do not stop brain cell decline.
More recently, two monoclonal antibodies have been FDA-approved for early-stage Alzheimer’s to target amyloid plaques (protein clumps in the brain linked to the disease):
- Lecanemab (Leqembi, approved 2023): Administered via IV every two weeks, it slows cognitive decline by about 27% over 18 months in mild cases, but it carries risks like brain swelling or bleeding.
- Donanemab (Kisunla, approved 2024): Given every four weeks, it reduces decline by 35% in early stages and allows treatment pauses once plaques clear, though side effects and high costs (around $26,500/year) limit access.
Promising Developments and ResearchWhile a cure remains elusive, 2025 has seen exciting progress in understanding and targeting Alzheimer’s mechanisms, with over 180 drugs in clinical trials (including 86 in Phase 2). Key highlights include:
- Immune system involvement: Blocking the STING molecule prevented cognitive decline in mice by addressing failed brain repair; human trials are underway.
- Viral links: Antiviral treatments for herpes simplex virus (HSV-1) reduced Alzheimer’s risk by 17% in infected individuals, suggesting infection prevention as a strategy.
- AI and diagnostics: AI predicts onset up to seven years early with 72% accuracy, and new blood tests detect plaques with 91% precision for earlier intervention.
- Repurposed drugs: Cancer drugs like saracatinib reversed memory loss in mice by protecting synapses, now in human trials.
- Brain implants: Graphene-based devices (e.g., from InBrain) could correct faulty signals, with dementia applications in development.
- Hormonal and gender factors: Estrogen decline in menopause raises risk in women; hormone therapies are being reevaluated.
- Ongoing trials: Tau tangle inhibitors, inflammation reducers (e.g., sargramostim), and amyloid-clearing drugs like Roche’s trontinemab (91% plaque reduction in early data) show potential.
Experts are optimistic, with 81% of surveyed Americans believing progression-stopping treatments will emerge within a decade. Lifestyle factors like exercise, heart-healthy diets, and blood pressure control may also delay onset. Consult a doctor for personalized advice, as early diagnosis via MRI or blood tests improves outcomes.
For further information please visit: https://www.axj.health/
“McDonald’s sells 6.5 million burgers in one single day.” “Even if you stretched one cow into a bunch of burgers, you’re still talking millions of cows just to keep up.” “Where are all these cows coming from?” “What the hell are we eating? Because if it ain’t cows, then what is it?”